

Philip Bejon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3418133/publications.pdf>

Version: 2024-02-01

194
papers

12,083
citations

34105

52
h-index

32842

100
g-index

218
all docs

218
docs citations

218
times ranked

10959
citing authors

#	ARTICLE	IF	CITATIONS
1	First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children. <i>New England Journal of Medicine</i> , 2011, 365, 1863-1875.	27.0	773
2	A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants. <i>New England Journal of Medicine</i> , 2012, 367, 2284-2295.	27.0	653
3	Oral versus Intravenous Antibiotics for Bone and Joint Infection. <i>New England Journal of Medicine</i> , 2019, 380, 425-436.	27.0	548
4	Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of Age. <i>New England Journal of Medicine</i> , 2008, 359, 2521-2532.	27.0	365
5	Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. <i>New England Journal of Medicine</i> , 2016, 374, 1647-1660.	27.0	355
6	Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children. <i>New England Journal of Medicine</i> , 2016, 374, 2519-2529.	27.0	336
7	Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine. <i>New England Journal of Medicine</i> , 2015, 373, 2025-2037.	27.0	332
8	Upregulation of TGF- β 2, FOXP3, and CD4+CD25+ Regulatory T Cells Correlates with More Rapid Parasite Growth in Human Malaria Infection. <i>Immunity</i> , 2005, 23, 287-296.	14.3	328
9	Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. <i>Lancet Infectious Diseases</i> , 2015, 15, 1450-1458.	9.1	262
10	Chronic Exposure to <i>Plasmodium falciparum</i> Is Associated with Phenotypic Evidence of B and T Cell Exhaustion. <i>Journal of Immunology</i> , 2013, 190, 1038-1047.	0.8	261
11	Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors. <i>Science</i> , 2021, 371, 79-82.	12.6	247
12	Four-Year Efficacy of RTS,S/AS01E and Its Interaction with Malaria Exposure. <i>New England Journal of Medicine</i> , 2013, 368, 1111-1120.	27.0	240
13	Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 4836-4841.	7.1	228
14	Stable and Unstable Malaria Hotspots in Longitudinal Cohort Studies in Kenya. <i>PLoS Medicine</i> , 2010, 7, e1000304.	8.4	221
15	The prevalence of <i>Plasmodium falciparum</i> in sub-Saharan Africa since 1900. <i>Nature</i> , 2017, 550, 515-518.	27.8	180
16	Examining the human infectious reservoir for <i>Plasmodium falciparum</i> malaria in areas of differing transmission intensity. <i>Nature Communications</i> , 2017, 8, 1133.	12.8	174
17	The Relationship between RTS,S Vaccine-Induced Antibodies, CD4+ T Cell Responses and Protection against <i>Plasmodium falciparum</i> Infection. <i>PLoS ONE</i> , 2013, 8, e61395.	2.5	163
18	Calculation of Liver to Blood Inocula, Parasite Growth Rates, and Preerythrocytic Vaccine Efficacy, from Serial Quantitative Polymerase Chain Reaction Studies of Volunteers Challenged with Malaria Sporozoites. <i>Journal of Infectious Diseases</i> , 2005, 191, 619-626.	4.0	152

#	ARTICLE	IF	CITATIONS
19	Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5–17 months in Kenya and Tanzania: a randomised controlled trial. <i>Lancet Infectious Diseases</i> , 2011, 11, 102-109.	9.1	152
20	Prevalence of vitamin D deficiency in Africa: a systematic review and meta-analysis. <i>The Lancet Global Health</i> , 2020, 8, e134-e142.	6.3	150
21	HIV Infection, Malnutrition, and Invasive Bacterial Infection among Children with Severe Malaria. <i>Clinical Infectious Diseases</i> , 2009, 49, 336-343.	5.8	146
22	A LAIR1 insertion generates broadly reactive antibodies against malaria variant antigens. <i>Nature</i> , 2016, 529, 105-109.	27.8	140
23	Innate Immune Responses to Human Malaria: Heterogeneous Cytokine Responses to Blood-Stage <i>Plasmodium falciparum</i> Correlate with Parasitological and Clinical Outcomes. <i>Journal of Immunology</i> , 2006, 177, 5736-5745.	0.8	138
24	Atypical B cells are part of an alternative lineage of B cells that participates in responses to vaccination and infection in humans. <i>Cell Reports</i> , 2021, 34, 108684.	6.4	134
25	A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya. <i>PLOS Clinical Trials</i> , 2006, 1, e29.	3.5	124
26	Durable Human Memory T Cells Quantifiable by Cultured Enzyme-Linked Immunospot Assays Are Induced by Heterologous Prime Boost Immunization and Correlate with Protection against Malaria. <i>Journal of Immunology</i> , 2005, 175, 5675-5680.	0.8	123
27	A micro-epidemiological analysis of febrile malaria in Coastal Kenya showing hotspots within hotspots. <i>ELife</i> , 2014, 3, e02130.	6.0	115
28	Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against <i>Plasmodium falciparum</i> infection in Kenyan adults. <i>Science Translational Medicine</i> , 2015, 7, 286re5.	12.4	113
29	Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naïve Individuals. <i>Journal of Infectious Diseases</i> , 2015, 211, 1076-1086.	4.0	110
30	Thick blood film examination for <i>Plasmodium falciparum</i> malaria has reduced sensitivity and underestimates parasite density. <i>Malaria Journal</i> , 2006, 5, 104.	2.3	101
31	Defining Childhood Severe <i>Falciparum</i> Malaria for Intervention Studies. <i>PLoS Medicine</i> , 2007, 4, e251.	8.4	101
32	Analysis of Immunity to Febrile Malaria in Children That Distinguishes Immunity from Lack of Exposure. <i>Infection and Immunity</i> , 2009, 77, 1917-1923.	2.2	98
33	An open dataset of <i>Plasmodium falciparum</i> genome variation in 7,000 worldwide samples. <i>Wellcome Open Research</i> , 2021, 6, 42.	1.8	97
34	Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to <i>Plasmodium falciparum</i> using sporozoites administered by intramuscular injection. <i>Frontiers in Microbiology</i> , 2014, 5, 686.	3.5	95
35	B Cell Memory to <i>Plasmodium falciparum</i> Blood-Stage Antigens in a Malaria-Endemic Area. <i>Journal of Infectious Diseases</i> , 2005, 191, 1623-1630.	4.0	91
36	A Phase 2a Randomized Study to Evaluate the Safety and Immunogenicity of the 1790GAHB Generalized Modules for Membrane Antigen Vaccine against <i>Shigella sonnei</i> Administered Intramuscularly to Adults from a Shigellosis-Endemic Country. <i>Frontiers in Immunology</i> , 2017, 8, 1884.	4.8	91

#	ARTICLE	IF	CITATIONS
37	Circumsporozoite-Specific T Cell Responses in Children Vaccinated with RTS,S/AS01E and Protection against <i>P falciparum</i> Clinical Malaria. <i>PLoS ONE</i> , 2011, 6, e25786.	2.5	89
38	The Induction and Persistence of T Cell IFN- γ Responses after Vaccination or Natural Exposure Is Suppressed by <i>Plasmodium falciparum</i> . <i>Journal of Immunology</i> , 2007, 179, 4193-4201.	0.8	88
39	Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 319-327.	9.1	87
40	Correlation of Memory T Cell Responses against TRAP with Protection from Clinical Malaria, and CD4+ CD25high T Cells with Susceptibility in Kenyans. <i>PLoS ONE</i> , 2008, 3, e2027.	2.5	82
41	Antigen-Specific IL-2 Secretion Correlates with NK Cell Responses after Immunization of Tanzanian Children with the RTS,S/AS01 Malaria Vaccine. <i>Journal of Immunology</i> , 2012, 188, 5054-5062.	0.8	77
42	Wind direction and proximity to larval sites determines malaria risk in Kilifi District in Kenya. <i>Nature Communications</i> , 2012, 3, 674.	12.8	73
43	Memory B cells are a more reliable archive for historical antimalarial responses than plasma antibodies in no-longer exposed children. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 8247-8252.	7.1	71
44	A threshold concentration of anti-merozoite antibodies is required for protection from clinical episodes of malaria. <i>Vaccine</i> , 2013, 31, 3936-3942.	3.8	71
45	A framework for Controlled Human Infection Model (CHIM) studies in Malawi: Report of a Wellcome Trust workshop on CHIM in Low Income Countries held in Blantyre, Malawi. <i>Wellcome Open Research</i> , 2017, 2, 70.	1.8	71
46	Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials. <i>American Journal of Tropical Medicine and Hygiene</i> , 2005, 73, 191-8.	1.4	71
47	Age, Spatial, and Temporal Variations in Hospital Admissions with Malaria in Kilifi County, Kenya: A 25-Year Longitudinal Observational Study. <i>PLoS Medicine</i> , 2016, 13, e1002047.	8.4	68
48	Changing Malaria Prevalence on the Kenyan Coast since 1974: Climate, Drugs and Vector Control. <i>PLoS ONE</i> , 2015, 10, e0128792.	2.5	65
49	Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization. <i>EBioMedicine</i> , 2017, 19, 107-118.	6.1	64
50	Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with <i>Plasmodium falciparum</i> Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults. <i>PLoS ONE</i> , 2013, 8, e57726.	2.5	64
51	Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 738-748.	9.1	62
52	COVID-19 transmission dynamics underlying epidemic waves in Kenya. <i>Science</i> , 2021, 374, 989-994.	12.6	62
53	Effect of the Pre-erythrocytic Candidate Malaria Vaccine RTS,S/AS01E on Blood Stage Immunity in Young Children. <i>Journal of Infectious Diseases</i> , 2011, 204, 9-18.	4.0	60
54	Extended Follow-Up Following a Phase 2b Randomized Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya. <i>PLoS ONE</i> , 2007, 2, e707.	2.5	57

#	ARTICLE	IF	CITATIONS
55	An Unsupported Preference for Intravenous Antibiotics. <i>PLoS Medicine</i> , 2015, 12, e1001825.	8.4	54
56	First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children. <i>PLoS ONE</i> , 2018, 13, e0208328.	2.5	53
57	Fraction of all hospital admissions and deaths attributable to malnutrition among children in rural Kenya. <i>American Journal of Clinical Nutrition</i> , 2008, 88, 1626-1631.	4.7	52
58	Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants. <i>Molecular Therapy</i> , 2016, 24, 1470-1477.	8.2	52
59	An open dataset of <i>Plasmodium falciparum</i> genome variation in 7,000 worldwide samples. <i>Wellcome Open Research</i> , 2021, 6, 42.	1.8	51
60	The Ratio of Monocytes to Lymphocytes in Peripheral Blood Correlates with Increased Susceptibility to Clinical Malaria in Kenyan Children. <i>PLoS ONE</i> , 2013, 8, e57320.	2.5	49
61	Translating the Immunogenicity of Prime-boost Immunization With ChAd63 and MVA ME-TRAP From Malaria Naive to Malaria-endemic Populations. <i>Molecular Therapy</i> , 2014, 22, 1992-2003.	8.2	49
62	Oral versus intravenous antibiotic treatment for bone and joint infections (OVIVA): study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 583.	1.6	48
63	Ethical considerations in Controlled Human Malaria Infection studies in low resource settings: Experiences and perceptions of study participants in a malaria Challenge study in Kenya. <i>Wellcome Open Research</i> , 2018, 3, 39.	1.8	48
64	Effect of transmission intensity on hotspots and micro-epidemiology of malaria in sub-Saharan Africa. <i>BMC Medicine</i> , 2017, 15, 121.	5.5	47
65	Estimating the burden of iron deficiency among African children. <i>BMC Medicine</i> , 2020, 18, 31.	5.5	47
66	Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 6 year old children in a malaria endemic area. <i>Vaccine</i> , 2006, 24, 4709-4715.	3.8	46
67	Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against <i>Plasmodium falciparum</i> Infection in Adults in Senegal. <i>PLoS ONE</i> , 2016, 11, e0167951.	2.5	46
68	Malaria hotspots defined by clinical malaria, asymptomatic carriage, PCR and vector numbers in a low transmission area on the Kenyan Coast. <i>Malaria Journal</i> , 2016, 15, 213.	2.3	46
69	Ethical considerations in Controlled Human Malaria Infection studies in low resource settings: Experiences and perceptions of study participants in a malaria Challenge study in Kenya. <i>Wellcome Open Research</i> , 2018, 3, 39.	1.8	46
70	A Statistical Interaction between Circumsporozoite Protein-Specific T Cell and Antibody Responses and Risk of Clinical Malaria Episodes following Vaccination with RTS,S/AS01E. <i>PLoS ONE</i> , 2012, 7, e52870.	2.5	43
71	A review of the frequencies of <i>Plasmodium falciparum</i> Kelch 13 artemisinin resistance mutations in Africa. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2021, 16, 155-161.	3.4	42
72	Safety Profile of the Viral Vectors of Attenuated Fowlpox Strain FP9 and Modified Vaccinia Virus Ankara Recombinant for Either of 2 Preerythrocytic Malaria Antigens, ME-TRAP or the Circumsporozoite Protein, in Children and Adults in Kenya. <i>Clinical Infectious Diseases</i> , 2006, 42, 1102-1110.	5.8	41

#	ARTICLE	IF	CITATIONS
73	Prolonged health worker strikes in Kenya- perspectives and experiences of frontline health managers and local communities in Kilifi County. <i>International Journal for Equity in Health</i> , 2020, 19, 23.	3.5	41
74	Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya. <i>Nature Communications</i> , 2021, 12, 3966.	12.8	40
75	Defining Clinical Malaria: The Specificity and Incidence of Endpoints from Active and Passive Surveillance of Children in Rural Kenya. <i>PLoS ONE</i> , 2010, 5, e15569.	2.5	40
76	Invasive Gram-negative bacilli are frequently resistant to standard antibiotics for children admitted to hospital in Kilifi, Kenya. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, 232-235.	3.0	39
77	Acute seizures attributable to falciparum malaria in an endemic area on the Kenyan coast. <i>Brain</i> , 2011, 134, 1519-1528.	7.6	39
78	Detecting Malaria Hotspots: A Comparison of Rapid Diagnostic Test, Microscopy, and Polymerase Chain Reaction. <i>Journal of Infectious Diseases</i> , 2017, 216, 1091-1098.	4.0	39
79	Estimating Individual Exposure to Malaria Using Local Prevalence of Malaria Infection in the Field. <i>PLoS ONE</i> , 2012, 7, e32929.	2.5	38
80	Iron Status and Associated Malaria Risk Among African Children. <i>Clinical Infectious Diseases</i> , 2019, 68, 1807-1814.	5.8	38
81	Repeated clinical malaria episodes are associated with modification of the immune system in children. <i>BMC Medicine</i> , 2019, 17, 60.	5.5	37
82	Ethical and scientific considerations on the establishment of a controlled human infection model for schistosomiasis in Uganda: report of a stakeholders' meeting held in Entebbe, Uganda.. <i>AAS Open Research</i> , 2018, 1, 2.	1.5	37
83	Seroprevalence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers in Kenya. <i>Clinical Infectious Diseases</i> , 2022, 74, 288-293.	5.8	36
84	Malaria is a cause of iron deficiency in African children. <i>Nature Medicine</i> , 2021, 27, 653-658.	30.7	35
85	Risk factors for recurrence after <i>Staphylococcus aureus</i> bacteraemia. A retrospective matched case-control study. <i>Journal of Infection</i> , 2009, 58, 411-416.	3.3	34
86	Malaria infection, disease and mortality among children and adults on the coast of Kenya. <i>Malaria Journal</i> , 2020, 19, 210.	2.3	34
87	Helminth Infection and Eosinophilia and the Risk of <i>Plasmodium falciparum</i> Malaria in 1- to 6-Year-Old Children in a Malaria Endemic Area. <i>PLoS Neglected Tropical Diseases</i> , 2008, 2, e164.	3.0	34
88	Serological Evidence of Discrete Spatial Clusters of <i>Plasmodium falciparum</i> Parasites. <i>PLoS ONE</i> , 2011, 6, e21711.	2.5	34
89	Observational study: 27 years of severe malaria surveillance in Kilifi, Kenya. <i>BMC Medicine</i> , 2019, 17, 124.	5.5	33
90	Effect of strikes by health workers on mortality between 2010 and 2016 in Kilifi, Kenya: a population-based cohort analysis. <i>The Lancet Global Health</i> , 2019, 7, e961-e967.	6.3	33

#	ARTICLE	IF	CITATIONS
91	Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial. <i>Lancet, The</i> , 2021, 397, 119-127.	13.7	33
92	Tracking the introduction and spread of SARS-CoV-2 in coastal Kenya. <i>Nature Communications</i> , 2021, 12, 4809.	12.8	32
93	Malaria infection and severe disease risks in Africa. <i>Science</i> , 2021, 373, 926-931.	12.6	32
94	Serial measurement of the C-reactive protein is a poor predictor of treatment outcome in prosthetic joint infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1590-1593.	3.0	31
95	Plasmodium falciparum Malaria in Children Aged 0-2 Years: The Role of Foetal Haemoglobin and Maternal Antibodies to Two Asexual Malaria Vaccine Candidates (MSP3 and GLURP). <i>PLoS ONE</i> , 2014, 9, e107965.	2.5	30
96	Lack of Avidity Maturation of Merozoite Antigen-Specific Antibodies with Increasing Exposure to Plasmodium falciparum amongst Children and Adults Exposed to Endemic Malaria in Kenya. <i>PLoS ONE</i> , 2012, 7, e52939.	2.5	28
97	Micro-epidemiological structuring of Plasmodium falciparum parasite populations in regions with varying transmission intensities in Africa. <i>Wellcome Open Research</i> , 2017, 2, 10.	1.8	27
98	A Genome Wide Association Study of Plasmodium falciparum Susceptibility to 22 Antimalarial Drugs in Kenya. <i>PLoS ONE</i> , 2014, 9, e96486.	2.5	27
99	Oral versus intravenous antibiotics for bone and joint infections: the OVIVA non-inferiority RCT. <i>Health Technology Assessment</i> , 2019, 23, 1-92.	2.8	27
100	Blood-stage challenge for malaria vaccine efficacy trials: a pilot study with discussion of safety and potential value. <i>American Journal of Tropical Medicine and Hygiene</i> , 2008, 78, 878-83.	1.4	27
101	Multiple functions of human T cells generated by experimental malaria challenge. <i>European Journal of Immunology</i> , 2009, 39, 3042-3051.	2.9	26
102	Malaria and Age Variably but Critically Control Hepcidin Throughout Childhood in Kenya. <i>EBioMedicine</i> , 2015, 2, 1478-1486.	6.1	26
103	KILchip v1.0: A Novel Plasmodium falciparum Merozoite Protein Microarray to Facilitate Malaria Vaccine Candidate Prioritization. <i>Frontiers in Immunology</i> , 2018, 9, 2866.	4.8	26
104	No Evidence of Plasmodium falciparum <i>k13</i> Artemisinin Resistance-Confering Mutations over a 24-Year Analysis in Coastal Kenya but a Near Complete Reversion to Chloroquine-Sensitive Parasites. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	26
105	Avidity of Anti-Circumsporozoite Antibodies following Vaccination with RTS,S/AS01E in Young Children. <i>PLoS ONE</i> , 2014, 9, e115126.	2.5	26
106	Identifying children with excess malaria episodes after adjusting for variation in exposure: identification from a longitudinal study using statistical count models. <i>BMC Medicine</i> , 2015, 13, 183.	5.5	25
107	Proteomic analysis of extracellular vesicles from a Plasmodium falciparum Kenyan clinical isolate defines a core parasite secretome. <i>Wellcome Open Research</i> , 2017, 2, 50.	1.8	25
108	Proteomic analysis of extracellular vesicles from a Plasmodium falciparum Kenyan clinical isolate defines a core parasite secretome. <i>Wellcome Open Research</i> , 0, 2, 50.	1.8	25

#	ARTICLE	IF	CITATIONS
109	Ethical and scientific considerations on the establishment of a controlled human infection model for schistosomiasis in Uganda: report of a stakeholders' meeting held in Entebbe, Uganda.. AAS Open Research, 2018, 1, 2.	1.5	24
110	Alternating vector immunizations encoding pre-erythrocytic malaria antigens enhance memory responses in a malaria endemic area. European Journal of Immunology, 2006, 36, 2264-2272.	2.9	23
111	Safety of the Malaria Vaccine Candidate, RTS,S/AS01E in 5 to 17 Month Old Kenyan and Tanzanian Children. PLoS ONE, 2010, 5, e14090.	2.5	23
112	Early Gamma Interferon and Interleukin-2 Responses to Vaccination Predict the Late Resting Memory in Malaria-Naïve and Malaria-Exposed Individuals. Infection and Immunity, 2006, 74, 6331-6338.	2.2	22
113	Improving statistical power in severe malaria genetic association studies by augmenting phenotypic precision. ELife, 2021, 10, .	6.0	22
114	Clearance of Asymptomatic P. falciparum Infections Interacts with the Number of Clones to Predict the Risk of Subsequent Malaria in Kenyan Children. PLoS ONE, 2011, 6, e16940.	2.5	21
115	The effect of declining exposure on T cell-mediated immunity to Plasmodium falciparum – an epidemiological ‘natural experiment’. BMC Medicine, 2016, 14, 143.	5.5	20
116	The ferroportin Q248H mutation protects from anemia, but not malaria or bacteremia. Science Advances, 2019, 5, eaaw0109.	10.3	20
117	Arterolane-piperaquine-mefloquine versus arterolane-piperaquine and artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial. Lancet Infectious Diseases, The, 2021, 21, 1395-1406.	9.1	20
118	Malaria exposure drives both cognate and bystander human B cells to adopt an atypical phenotype. European Journal of Immunology, 2020, 50, 1187-1194.	2.9	19
119	Trends in bednet ownership and usage, and the effect of bednets on malaria hospitalization in the Kilifi Health and Demographic Surveillance System (KHDSS): 2008-2015. BMC Infectious Diseases, 2017, 17, 720.	2.9	17
120	Evaluating the Performance of Malaria Genetics for Inferring Changes in Transmission Intensity Using Transmission Modeling. Molecular Biology and Evolution, 2021, 38, 274-289.	8.9	17
121	Pooled testing conserves SARS-CoV-2 laboratory resources and improves test turn-around time: experience on the Kenyan Coast. Wellcome Open Research, 2020, 5, 186.	1.8	17
122	Prevalence and predictors of vitamin D deficiency in young African children. BMC Medicine, 2021, 19, 115.	5.5	17
123	Interactions between Age and ITN Use Determine the Risk of Febrile Malaria in Children. PLoS ONE, 2009, 4, e8321.	2.5	17
124	Deliberately infecting healthy volunteers with malaria parasites: Perceptions and experiences of participants and other stakeholders in a Kenyan-based malaria infection study. Bioethics, 2020, 34, 819-832.	1.4	16
125	Feedback of Research Findings for Vaccine Trials: Experiences from Two Malaria Vaccine Trials Involving Healthy Children on the Kenyan Coast. Developing World Bioethics, 2013, 13, 48-56.	0.9	15
126	Dynamics and role of antibodies to Plasmodium falciparum merozoite antigens in children living in two settings with differing malaria transmission intensity. Vaccine, 2016, 34, 160-166.	3.8	15

#	ARTICLE	IF	CITATIONS
127	Cost-effectiveness of oral versus intravenous antibiotics (OVIVA) in patients with bone and joint infection: evidence from a non-inferiority trial. Wellcome Open Research, 0, 4, 108.	1.8	15
128	Endemic chikungunya fever in Kenyan children: a prospective cohort study. BMC Infectious Diseases, 2021, 21, 186.	2.9	14
129	Geographic-genetic analysis of Plasmodium falciparum parasite populations from surveys of primary school children in Western Kenya. Wellcome Open Research, 2017, 2, 29.	1.8	14
130	Comparative performance of WANTAI ELISA for total immunoglobulin to receptor binding protein and an ELISA for IgG to spike protein in detecting SARS-CoV-2 antibodies in Kenyan populations. Journal of Clinical Virology, 2022, 146, 105061.	3.1	14
131	An optimisation of four SARS-CoV-2 qRT-PCR assays in a Kenyan laboratory to support the national COVID-19 rapid response teams. Wellcome Open Research, 2020, 5, 162.	1.8	13
132	Pooled testing conserves SARS-CoV-2 laboratory resources and improves test turn-around time: experience on the Kenyan Coast. Wellcome Open Research, 2020, 5, 186.	1.8	13
133	Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin G Antibody Seroprevalence Among Truck Drivers and Assistants in Kenya. Open Forum Infectious Diseases, 2021, 8, ofab314.	0.9	12
134	Variation in the effectiveness of insecticide treated nets against malaria and outdoor biting by vectors in Kilifi, Kenya. Wellcome Open Research, 2017, 2, 22.	1.8	12
135	Variation in the effectiveness of insecticide treated nets against malaria and outdoor biting by vectors in Kilifi, Kenya. Wellcome Open Research, 2017, 2, 22.	1.8	12
136	Epidemiology of COVID-19 infections on routine polymerase chain reaction (PCR) and serology testing in Coastal Kenya. Wellcome Open Research, 2022, 7, 69.	1.8	12
137	Malaria vaccines: past, present and future. Archives of Disease in Childhood, 2013, 98, 981-985.	1.9	10
138	Single low-dose primaquine for blocking transmission of Plasmodium falciparum malaria – a proposed model-derived age-based regimen for sub-Saharan Africa. BMC Medicine, 2018, 16, 11.	5.5	10
139	Gametocyte carriage in an era of changing malaria epidemiology: A 19-year analysis of a malaria longitudinal cohort. Wellcome Open Research, 2019, 4, 66.	1.8	10
140	Geographic-genetic analysis of Plasmodium falciparum parasite populations from surveys of primary school children in Western Kenya. Wellcome Open Research, 0, 2, 29.	1.8	10
141	A seven-year study on the effect of the pre-erythrocytic malaria vaccine candidate RTS,S/AS01E on blood stage immunity in young Kenyan children. Wellcome Open Research, 2019, 4, 42.	1.8	10
142	Gametocyte carriage in an era of changing malaria epidemiology: A 19-year analysis of a malaria longitudinal cohort. Wellcome Open Research, 2019, 4, 66.	1.8	10
143	Congenital microcephaly unrelated to flavivirus exposure in coastal Kenya. Wellcome Open Research, 2019, 4, 179.	1.8	10
144	Characterization of Naturally Acquired Immunity to a Panel of Antigens Expressed in Mature P. falciparum Gametocytes. Frontiers in Cellular and Infection Microbiology, 2021, 11, 774537.	3.9	10

#	ARTICLE	IF	CITATIONS
145	Vitamin D Deficiency and Its Association with Iron Deficiency in African Children. <i>Nutrients</i> , 2022, 14, 1372.	4.1	10
146	Seven-year kinetics of RTS, S/AS01-induced anti-CSP antibodies in young Kenyan children. <i>Malaria Journal</i> , 2021, 20, 452.	2.3	10
147	The relationship between facility-based malaria test positivity rate and community-based parasite prevalence. <i>PLoS ONE</i> , 2020, 15, e0240058.	2.5	9
148	Cost-effectiveness of oral versus intravenous antibiotics (OVIVA) in patients with bone and joint infection: evidence from a non-inferiority trial. <i>Wellcome Open Research</i> , 2019, 4, 108.	1.8	9
149	Quantitative PCR Evaluation of Cellular Immune Responses in Kenyan Children Vaccinated with a Candidate Malaria Vaccine. <i>PLoS ONE</i> , 2009, 4, e8434.	2.5	8
150	Immune Responses to Gametocyte Antigens in a Malaria Endemic Population—The African falciparum Context: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2019, 10, 2480.	4.8	8
151	Iron Deficiency Is Associated With Reduced Levels of Plasmodium falciparum-specific Antibodies in African Children. <i>Clinical Infectious Diseases</i> , 2020, 73, 43-49.	5.8	8
152	Revealing the extent of the first wave of the COVID-19 pandemic in Kenya based on serological and PCR-test data. <i>Wellcome Open Research</i> , 0, 6, 127.	1.8	8
153	Understanding the benefits and burdens associated with a malaria human infection study in Kenya: experiences of study volunteers and other stakeholders. <i>Trials</i> , 2021, 22, 494.	1.6	8
154	Bayesian evaluation of the performance of three diagnostic tests for Plasmodium falciparum infection in a low-transmission setting in Kilifi County, Kenya. <i>Wellcome Open Research</i> , 2019, 4, 67.	1.8	8
155	Spatio-temporal distribution of antimalarial drug resistant gene mutations in a Plasmodium falciparum parasite population from Kilifi, Kenya: A 25-year retrospective study. <i>Wellcome Open Research</i> , 0, 7, 45.	1.8	8
156	10-year longitudinal study of malaria in children: Insights into acquisition and maintenance of naturally acquired immunity. <i>Wellcome Open Research</i> , 2021, 6, 79.	1.8	7
157	Detection of SARS-CoV-2 variant 501Y.V2 in Comoros Islands in January 2021. <i>Wellcome Open Research</i> , 2021, 6, 192.	1.8	7
158	Randomized, double-blinded, controlled non-inferiority trials evaluating the immunogenicity and safety of fractional doses of Yellow Fever vaccines in Kenya and Uganda. <i>Wellcome Open Research</i> , 2019, 4, 182.	1.8	7
159	Micro-epidemiological structuring of Plasmodium falciparum parasite populations in regions with varying transmission intensities in Africa.. <i>Wellcome Open Research</i> , 0, 2, 10.	1.8	7
160	Individual-level variations in malaria susceptibility and acquisition of clinical protection. <i>Wellcome Open Research</i> , 2021, 6, 22.	1.8	6
161	Variation in the effectiveness of insecticide treated nets against malaria and outdoor biting by vectors in Kilifi, Kenya. <i>Wellcome Open Research</i> , 0, 2, 22.	1.8	6
162	Transcriptomic signatures induced by the Ebola virus vaccine rVSV ^{GP} -ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study. <i>Lancet Microbe</i> , The, 2022, 3, e113-e123.	7.3	6

#	ARTICLE	IF	CITATIONS
163	Clearing asymptomatic parasitaemia increases the specificity of the definition of mild febrile malaria. <i>Vaccine</i> , 2007, 25, 8198-8202.	3.8	5
164	Malaria vaccine development: Lessons from the field. <i>European Journal of Immunology</i> , 2009, 39, 2007-2010.	2.9	5
165	Hepcidin regulation in Kenyan children with severe malaria and non-typhoidal <i>Salmonella</i> bacteremia. <i>Haematologica</i> , 2022, 107, 1589-1598.	3.5	5
166	Incidence of chikungunya virus infections among Kenyan children with neurological disease, 2014â€“2018: A cohort study. <i>PLoS Medicine</i> , 2022, 19, e1003994.	8.4	5
167	Individual-level variations in malaria susceptibility and acquisition of clinical protection. <i>Wellcome Open Research</i> , 0, 6, 22.	1.8	4
168	Bayesian evaluation of the performance of three diagnostic tests for <i>Plasmodium falciparum</i> infection in a low-transmission setting in Kilifi County, Kenya. <i>Wellcome Open Research</i> , 2019, 4, 67.	1.8	4
169	Interferon-gamma polymorphisms and risk of iron deficiency and anaemia in Gambian children. <i>Wellcome Open Research</i> , 2020, 5, 40.	1.8	4
170	Determinants of improvement trends in health workersâ€™ compliance with outpatient malaria case-management guidelines at health facilities with available â€œtest and treatâ€• commodities in Kenya. <i>PLoS ONE</i> , 2021, 16, e0259020.	2.5	4
171	10-year longitudinal study of malaria in children: Insights into acquisition and maintenance of naturally acquired immunity. <i>Wellcome Open Research</i> , 0, 6, 79.	1.8	4
172	An optimization of four SARS-CoV-2 qRT-PCR assays in a Kenyan laboratory to support the national COVID-19 rapid response teams. <i>Wellcome Open Research</i> , 0, 5, 162.	1.8	4
173	Targeted Amplicon Deep Sequencing for Monitoring Antimalarial Resistance Markers in Western Kenya. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0194521.	3.2	4
174	Cost-effectiveness of oral versus intravenous antibiotics (OVIVA) in patients with bone and joint infection: evidence from a non-inferiority trial. <i>Wellcome Open Research</i> , 0, 4, 108.	1.8	3
175	Interferon-gamma polymorphisms and risk of iron deficiency and anaemia in Gambian children. <i>Wellcome Open Research</i> , 2020, 5, 40.	1.8	3
176	Mortality in rural coastal Kenya measured using the Kilifi Health and Demographic Surveillance System: a 16-year descriptive analysis. <i>Wellcome Open Research</i> , 0, 6, 327.	1.8	3
177	<i>Plasmodium falciparum</i> -Specific Memory B-Cell and Antibody Responses Are Associated With Immunity in Children Living in an Endemic Area of Kenya. <i>Frontiers in Immunology</i> , 2022, 13, 799306.	4.8	3
178	Genomic Epidemiology of SARS-CoV-2 in Seychelles, 2020â€“2021. <i>Viruses</i> , 2022, 14, 1318.	3.3	3
179	Investigating the drivers of the spatio-temporal patterns of genetic differences between <i>Plasmodium falciparum</i> malaria infections in Kilifi County, Kenya. <i>Scientific Reports</i> , 2019, 9, 19018.	3.3	2
180	Antibody Responses to Crude Gametocyte Extract Predict <i>Plasmodium falciparum</i> Gametocyte Carriage in Kenya. <i>Frontiers in Immunology</i> , 2020, 11, 609474.	4.8	2

#	ARTICLE	IF	CITATIONS
181	OUP accepted manuscript. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2022, , .	1.8	2
182	Ethical considerations around volunteer payments in a malaria human infection study in Kenya: an embedded empirical ethics study. BMC Medical Ethics, 2022, 23, 46.	2.4	2
183	Malaria parasites hide in plain sight in the dry season. Nature Medicine, 2020, 26, 1816-1818.	30.7	1
184	Impact of Plasmodium falciparum small-sized extracellular vesicles on host peripheral blood mononuclear cells. Wellcome Open Research, 0, 5, 197.	1.8	1
185	Comparing drug regimens for clearance of malaria parasites in asymptomatic adults using PCR in Kilifi County, Kenya: an open-label randomised controlled clinical trial (MalPaC). Wellcome Open Research, 0, 5, 36.	1.8	1
186	Bayesian evaluation of the performance of three diagnostic tests for Plasmodium falciparum infection in a low-transmission setting in Kilifi County, Kenya. Wellcome Open Research, 0, 4, 67.	1.8	1
187	Impact of Plasmodium falciparum small-sized extracellular vesicles on host peripheral blood mononuclear cells. Wellcome Open Research, 0, 5, 197.	1.8	1
188	Revealing the extent of the first wave of the COVID-19 pandemic in Kenya based on serological and PCR-test data. Wellcome Open Research, 0, 6, 127.	1.8	1
189	The impact of intermittent presumptive treatment for malaria in pregnancy on hospital birth outcomes on the Kenyan coast. Clinical Infectious Diseases, 0, , .	5.8	1
190	Analysis of Immunity to Febrile Malaria in Children That Distinguishes Immunity from Lack of Exposure. Infection and Immunity, 2011, 79, 1804-1804.	2.2	0
191	Maintaining laboratory quality assurance and safety in a pandemic: Experiences from the KEMRI-Wellcome Trust Research Programme laboratory's COVID-19 response. Wellcome Open Research, 0, 6, 205.	1.8	0
192	Maintaining laboratory quality assurance and safety in a pandemic: Experiences from the KEMRI-Wellcome Trust Research Programme laboratory's COVID-19 response. Wellcome Open Research, 0, 6, 205.	1.8	0
193	Targeted Amplicon deep sequencing of ama1 and mdr1 to track within-host P. falciparum diversity throughout treatment in a clinical drug trial. Wellcome Open Research, 0, 7, 95.	1.8	0
194	Undertaking Community Engagement for a Controlled Human Malaria Infection Study in Kenya: Approaches and Lessons Learnt. Frontiers in Public Health, 2022, 10, 793913.	2.7	0